نتایج جستجو برای: cyp2b6

تعداد نتایج: 1820  

Journal: :The Journal of antimicrobial chemotherapy 2011
Christoph Wyen Heidy Hendra Marco Siccardi Martin Platten Hans Jaeger Thomas Harrer Stefan Esser Johannes R Bogner Norbert H Brockmeyer Bernhard Bieniek Juergen Rockstroh Christian Hoffmann Albrecht Stoehr Claudia Michalik Verena Dlugay Alexander Jetter Heribert Knechten Hartwig Klinker Adriane Skaletz-Rorowski Gerd Fätkenheuer Deirdre Egan David J Back Andrew Owen

OBJECTIVES Cytochrome P450 2B6 (CYP2B6) is responsible for the metabolic clearance of efavirenz and single nucleotide polymorphisms (SNPs) in the CYP2B6 gene are associated with efavirenz pharmacokinetics. Since the constitutive androstane receptor (CAR) and the pregnane X receptor (PXR) correlate with CYP2B6 in liver, and a CAR polymorphism (rs2307424) and smoking correlate with efavirenz plas...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2011
Jae Yong Chung Joo-Youn Cho Hyeong-Seok Lim Jung-Ryul Kim Kyung-Sang Yu Kyoung Soo Lim Sang-Goo Shin In-Jin Jang

We investigated genetic polymorphisms in the pregnane X receptor (NR1I2) in Korean individuals (n = 83) and the effects of NR1I2 genotypes on rifampin-mediated induction of bupropion hydroxylation. The pharmacokinetics of bupropion and hydroxybupropion were evaluated after an oral dose of bupropion (150 mg) administered before and after rifampin treatment for 7 days in 35 healthy subjects. The ...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2011
Masashi Honda Yuka Muroi Yuichiro Tamaki Daisuke Saigusa Naoto Suzuki Yoshihisa Tomioka Yoichi Matsubara Akifumi Oda Noriyasu Hirasawa Masahiro Hiratsuka

Artemether (AM) is one of the most effective antimalarial drugs. The elimination half-life of AM is very short, and it shows large interindividual variability in pharmacokinetic parameters. The aim of this study was to identify cytochrome P450 (P450) isozymes responsible for the demethylation of AM and to evaluate functional differences between 26 CYP2B6 allelic variants in vitro. Of 14 recombi...

Journal: :The Journal of pharmacology and experimental therapeutics 2003
Margit Spatzenegger Hong Liu Qinmi Wang Andrea Debarber Dennis R Koop James R Halpert

Human CYP2B6 and CYP2E1 were used to investigate the extent to which differential substrate selectivities between cytochrome P450 subfamilies reflect differences in active-site residues as opposed to distinct arrangement of the backbone of the enzymes. Reciprocal CYP2B6 and CYP2E1 mutants at active-site positions 103, 209, 294, 363, 367, and 477 (numbering according to CYP2B6) were characterize...

Journal: :The Journal of antimicrobial chemotherapy 2014
Fred S Sarfo Yuan Zhang Deirdre Egan Lambert A Tetteh Richard Phillips George Bedu-Addo Maame Anima Sarfo Saye Khoo Andrew Owen David R Chadwick

OBJECTIVES Efavirenz is widely used in first-line antiretroviral therapy in sub-Saharan Africa. However, exposure to efavirenz shows marked interindividual variability that is genetically mediated with potential for important pharmacodynamic consequences. The aims of this study were to assess the frequencies of CYP2B6, CYP2A6, UGT2B7 and CAR single nucleotide polymorphisms (SNPs) and their impa...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2007
Robert L Walsky R Scott Obach

The use of selective chemical inhibitors of human cytochrome P450 (P450) enzymes represents a powerful method by which the relative contributions of various human P450 enzymes to the metabolism of drugs can be determined. However, the identification of CYP2B6 in the metabolism of drugs has been more challenging because of the lack of a well established inhibitor of this enzyme. In this report, ...

2014
Jackson K. Mukonzo Joel S. Owen Jasper Ogwal-Okeng Ronald B. Kuteesa Sarah Nanzigu Nelson Sewankambo Lehana Thabane Lars L. Gustafsson Colin Ross Eleni Aklillu

BACKGROUND Pharmacogenetics contributes to inter-individual variability in pharmacokinetics (PK) of efavirenz (EFV), leading to variations in both efficacy and toxicity. The purpose of this study was to assess the effect of genetic factors on EFV pharmacokinetics, treatment outcomes and genotype based EFV dose recommendations for adult HIV-1 infected Ugandans. METHODS In total, 556 steady-sta...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2012
Cong Xu Evan T Ogburn Yingying Guo Zeruesenay Desta

The mechanism by which CYP2B6*6 allele alters drug metabolism in vitro and in vivo is not fully understood. To test the hypothesis that altered substrate binding and/or catalytic properties contribute to its functional consequences, efavirenz 8-hydroxylation and bupropion 4-hydroxylation were determined in CYP2B6.1 and CYP2B6.6 proteins expressed without and with cytochrome b5 (Cyt b5) and in h...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2009
Aik Jiang Lau Thomas K H Chang

Cytochrome P450 2B6 (CYP2B6) is expressed predominantly in human liver. It catalyzes the oxidative biotransformation of various drugs, including bupropion, which is an antidepressant and a tobacco use cessation agent. Serious adverse effects of high dosages of bupropion have been reported, including the onset of seizure. As Ginkgo biloba extract may be consumed with bupropion or another CYP2B6 ...

Journal: :Antimicrobial agents and chemotherapy 2010
Monidarin Chou Julie Bertrand Olivier Segeral Céline Verstuyft Laurence Borand Emmanuelle Comets Clotilde Le Tiec Laurent Becquemont Vara Ouk France Mentre Anne-Marie Taburet

The aims of this ANRS12154 open-label, single-center, multiple-dose pharmacokinetic study were to characterize nevirapine pharmacokinetics in a Cambodian population of HIV-infected patients and to identify environmental and genetic factors of variability, focusing on the CYP2B6, CYP3A5, and ABCB1 (MDR1) genes. A total of 170 Cambodian HIV-infected patients were included. Nevirapine trough conce...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید